PMID- 29517349
OWN - NLM
STAT- MEDLINE
DCOM- 20181025
LR  - 20181025
IS  - 1744-8301 (Electronic)
IS  - 1479-6694 (Linking)
VI  - 14
IP  - 17
DP  - 2018 Jul
TI  - miR-181a targets GATA6 to inhibit the progression of human laryngeal squamous 
      cell carcinoma.
PG  - 1741-1753
LID - 10.2217/fon-2018-0064 [doi]
AB  - AIM: We sought to determine the function of miR-181a/GATA6 pathway in the 
      progression of laryngeal squamous cell carcinoma (LSCC). MATERIALS & METHODS: The 
      expression of miR-181a and GATA6 were detected using quantitative real-time-PCR 
      and western blotting in 127 LSCC samples and 32 corresponding control mucosa 
      tissues. Cell death, migration and apoptosis were measured in Hep-2 cells using 
      3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT), 
      Transwell migration assay and apoptosis assay, respectively. The prognosis was 
      determined by the follow-up, univariate analysis and multivariate analysis. 
      RESULTS: We observed decreased miR-181a levels and increased GATA6 expression in 
      LSCC samples compared with control mucosa tissues. Transfection of miR-181a 
      decreased GATA6 expression, suppressed migration and promoted apoptosis in Hep-2 
      cells. Furthermore, silencing GATA6 suppressed cell migration and promoted 
      apoptosis in Hep-2 cells. Notably, patients with high miR-181a levels had a 
      longer life span. CONCLUSION: MiR-181a inhibits LSCC progression via suppressing 
      GATA6 expression. MiR-181a is an independent prognostic factor in LSCC patients.
FAU - Zhao, Xudong
AU  - Zhao X
AD  - Department of Otorhinolaryngology, Shengjing Hospital, China Medical University, 
      Shenyang 110004, PR China.
FAU - Zhang, Wei
AU  - Zhang W
AD  - Department of Endocrinology Shengjing Hospital, China Medical University, 
      Shenyang 110004, PR China.
FAU - Ji, Wenyue
AU  - Ji W
AD  - Department of Otorhinolaryngology, Shengjing Hospital, China Medical University, 
      Shenyang 110004, PR China.
LA  - eng
PT  - Journal Article
DEP - 20180308
PL  - England
TA  - Future Oncol
JT  - Future oncology (London, England)
JID - 101256629
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (GATA6 Transcription Factor)
RN  - 0 (GATA6 protein, human)
RN  - 0 (MIrn181 microRNA, human)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Apoptosis
MH  - Biomarkers, Tumor/genetics/*metabolism
MH  - Carcinoma, Squamous Cell/*genetics/metabolism/pathology
MH  - Case-Control Studies
MH  - Cell Movement
MH  - Cell Proliferation
MH  - Disease Progression
MH  - Female
MH  - Follow-Up Studies
MH  - GATA6 Transcription Factor/genetics/*metabolism
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Laryngeal Neoplasms/*genetics/metabolism/pathology
MH  - Male
MH  - MicroRNAs/*genetics
MH  - Middle Aged
MH  - Prognosis
MH  - Survival Rate
MH  - Tumor Cells, Cultured
OTO - NOTNLM
OT  - GATA6
OT  - LSCC
OT  - cervical metastasis
OT  - laryngeal cancer
OT  - miR-181a
OT  - prognosis
OT  - tumor progression
EDAT- 2018/03/09 06:00
MHDA- 2018/10/26 06:00
CRDT- 2018/03/09 06:00
PHST- 2018/03/09 06:00 [pubmed]
PHST- 2018/10/26 06:00 [medline]
PHST- 2018/03/09 06:00 [entrez]
AID - 10.2217/fon-2018-0064 [doi]
PST - ppublish
SO  - Future Oncol. 2018 Jul;14(17):1741-1753. doi: 10.2217/fon-2018-0064. Epub 2018 
      Mar 8.